CD70 antigen Antibodies

CD70 antigen (CD70)

Cytokine that binds to CD27. Plays a role in T-cell activation.

Induces the proliferation of costimulated T-cells and enhances the generation of cytolytic T-cells. .

Gene Information

Human
Gene Name:	CD70
Uniprot:	P32970
Entrez:	970

Family

Belongs to:
tumor necrosis factor family

Alternative Names

CD27 Ligand; CD27-L; CD27LCD27 ligand; CD27LG; CD70 molecule; CD70; Ki-24 antigen; surface antigen CD70; TNFSF7; TNFSF7CD70 antigen; tumor necrosis factor (ligand) superfamily, member 7; Tumor necrosis factor ligand superfamily member 7

Molecular Weight

Mass (kDA):
21.118 kDA

Genomic Context

Human
Location:	19p13.3
Sequence:	19; NC_000019.10 (6581648..6591150, complement)

Subcellular Localizations

Membrane; Single-pass type II membrane protein.

Diseases

• Neoplasms
• Malignant Neoplasms
• Lymphoma
• Carcinoma
• Lupus Erythematosus, Systemic
• Autoimmune Reaction
• Inflammation
• Leukemia
• Virus Diseases
• Immunologic Deficiency Syndromes
• Malignant Paraganglionic Neoplasm
• Autoimmune Diseases
• Hiv Infections

• Melanoma
• Renal Cell Carcinoma
• Autoimmunity
• Influenza
• Kidney Neoplasm
• Infective Disorder
• Neoplasm Metastasis

Pathways

• Cell Activation
• Cell Proliferation
• Secretion
• Immune Response
• Pathogenesis
• T Cell Activation
• Methylation
• T Cell Proliferation
• Demethylation
• Dna Methylation
• Cell Differentiation
• B Cell Activation
• Cytokine Production

• Dna Hypomethylation
• Cell Development
• T Cell Differentiation
• Dna Demethylation
• B Cell Proliferation
• Cell Growth
• Lymphocyte Activation

PTMs

• Methylation
• Demethylation
• Phosphorylation
• Cleavage

• Acetylation
• Glycosylation
• Reduction
• Deacetylation

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/CD70

Boster Bio - Best Uses Of The CD70 Marker

Boster Bio's CD70 AlloCART therapy is something you might be considering. However, you may have heard of the CD70 anti-CD70 Marker. But what exactly does this therapy do? What's it good for? This innovative treatment is described in detail below. Continue reading to learn about CD70 AlloCAR Therapy for AML/RA.

Boster Bio Anti-CD70 Marker

In vivo studies have shown a role of CD70. The CD70+ APCs of mice were found in the gut lamina propria. They are constitutively expressed in mice and mediate the expansion of Ag-specific T cell populations in the gut mucosa. These findings may be useful for future studies, even though no studies have been conducted on CD70 expression in humans. It is crucial to study in vivo CD70-expressing APCs for understanding the mechanisms behind Ag-specific T cells differentiation.

CD70 is a cluster protein of differentiation 70 encoded by CD70. It is a member of the tumor necrosis factor ligand family and is found on activated T cells. CD70 is a costimulator of T cell proliferation and enhances the production of cytolytic cells. CD70's amino acid sequence and that of its related proteins are 19 to 24 percent alike. There is currently no CD70 kit or component that is commercially available. You will need a Microplate Reader and pipettes that can dispense volumes of 0.5-1 milliliters if you are interested in doing a study of this antigen.

This study revealed that anti-CD70 Ab blocks the binding of CD70 and CD27. Anti-CD70Ab also interacts with Fc-dependent functionor functions, reducing autoantibodies production and increasing disease severity. Anti-CD70 treatment also reduces joint inflammation caused by autoantibodies. As a result, the anti-CD70 Ab has a broad range of uses.

CD70 AlloCAR-T therapy for AML

The CD70 AlloCAR-T therapy is a promising new strategy to treat CD70-positive AML. It works by preventing the immune system from attacking diseased cells, while allowing normal hemopoiesis to continue. The treatment involves observing the patient's immune response to the virus-specific T-cells. It is crucial to monitor the response of the patient and respond accordingly.

CD70-targeted immunetherapies are being tested in clinical and preclinical settings. This will help improve the outcomes for patients with cancer. The company aims at making CD70-targeting therapies accessible to patients with cancer in near future. Fig. 4 shows an overview of the various strategies. Boster Bio is one company currently investigating the CD70 AlloCART therapy for AML.

Combining radiotherapy and CD70 AlloCAR-T therapy has produced promising results. Cusatuzumab, in combination with HMA, effectively eliminated CD70-expressing SSCs and induced stem cell differentiation. Patients' immune systems are compromised, so CD70-targeted therapies may be difficult to use. That's why it's critical to find an appropriate treatment strategy for AML.

Gemtuzumabozogamicin, a monoclonal antibody based immunotherapies, has also been demonstrated to be effective in CD70-directed AML. flotuzumab is another candidate for combination therapy. It is a bispecific DART (r) antibody to CD3e/CD123. Further studies will determine which of these agents will be most appropriate in a particular immunotherapy regimen. Further studies will improve the role of antibody based therapies in post-hemopoietic tissue transplant.

CD70 is a key target in alloCART therapies. However it remains unclear which drugs will be most effective in treating this condition. Five anti-CD70 CAR–T therapies are currently being evaluated in phase I/II clinical trial. CD70-targeted therapies have shown promising results in the treatment of solid tumors and hematological malignancies. However, many obstacles must still be overcome to ensure the treatment is safe and effective.

Seattle Genetics faced significant difficulties when trying to develop ADC compounds that could be used in AML treatment. Additionally to being unsatisfactory the combination Boster Bio's ALLO316 with Vidaza, a chemo-drug, has sparked a number clinical trials. In phase I of the clinical trial, the combination alloCAR T and SEA CD70 is still being evaluated.

The Argx-110 targeted CD70 showed promising anti-leukemic properties in clinical trials. Trudel GC was the lead author of the study. He led the phase II CULMINATE trial with newly diagnosed AML patients, who are not eligible for intensive chemotherapy.

Relapsed or refractory patients with B-cell lymphoma may be interested in the CD70 AlloCART T therapy for AML. Researchers from UCSF, Boster Bio and UCSF discovered that CD70/CD27 -targeted CART cells induce a relapseless syndrome and cytokine-release. These results suggest that Boster Bio's new therapy will significantly change the treatment landscape for B-ALL.

CD70 AlloCART T therapy for RA

A clinical-stage biotechnology company has pioneered the development of AlloCAR-T therapies for the treatment and prevention of RA. It uses a CD70-specific T cells. The company recently presented preliminary data in its Allo316 study to the 62nd American Society of Hematology. The trial has enrolled seven patients to date, although one patient had to be discontinued from the trial due to an adverse event related to lymphodepletion.